Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity-Reference-Cited by-同舟云学术

Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity

Published:2022-04-25 Issue:9 Volume:88 Page:4121-4133
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Kvitne Kine Eide¹^ORCID,Krogstad Veronica¹,Wegler Christine²³^ORCID,Johnson Line Kristin⁴,Kringen Marianne K.⁵⁶,Hovd Markus Herberg¹^ORCID,Hertel Jens K.⁴,Heijer Maria⁷,Sandbu Rune⁴⁸,Skovlund Eva⁹,Artursson Per¹⁰,Karlsson Cecilia¹¹¹²,Andersson Shalini¹³,Andersson Tommy B.³,Hjelmesæth Jøran⁴¹⁴,Åsberg Anders¹¹⁵^ORCID,Jansson‐Löfmark Rasmus³,Christensen Hege¹,Robertsen Ida¹^ORCID

Affiliation:

1. Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy University of Oslo Oslo Norway

2. Department of Pharmacy Uppsala University Uppsala Sweden

3. DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, AstraZeneca Mölndal Sweden

4. The Morbid Obesity Center Vestfold Hospital Trust Tønsberg Norway

5. Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway

6. Department of Health Sciences Oslo Metropolitan University Oslo Norway

7. Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences BioPharmaceuticals R&D, AstraZeneca Mölndal Sweden

8. Department of Surgery Vestfold Hospital Trust Tønsberg Norway

9. Department of Public Health and Nursing Norwegian University of Science and Technology, NTNU Trondheim Norway

10. Department of Pharmacy and Science for Life Laboratory Uppsala University Uppsala Sweden

11. Late‐stage Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&D, AstraZeneca Mölndal Sweden

12. Department of Molecular and Clinical Medicine Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden

13. Research and Early Development, Discovery Sciences BioPharmaceuticals R&D, AstraZeneca Mölndal Sweden

14. Department of Endocrinology, Morbid Obesity and Preventive Medicine Institute of Clinical Medicine, University of Oslo Oslo Norway

15. Department of Transplantation Medicine Oslo University Hospital Oslo Norway

Funder

Vetenskapsrådet

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15349

Reference52 articles.

1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

2. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals

3. Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis

4. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

5. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of CYP 2C9 rs1799853 and rs1057910 Polymorphism on Plasma Losartan Metabolic Ratio in a Sample of Iraqi Hypertensive Patients;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2024-09-14

2. Redefining Statin Dosage Post‐Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach;The Journal of Clinical Pharmacology;2024-08-05

3. Impact of obesity and roux‐en‐Y gastric bypass on the pharmacokinetics of (R)‐ and (S)‐omeprazole and intragastric pH;CPT: Pharmacometrics & Systems Pharmacology;2024-06-24

4. Rerouting cardiovascular management following gastric bypass surgery: Dose optimization of carvedilol using population‐based analysis;British Journal of Clinical Pharmacology;2024-06-09

5. Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients;Therapeutic Drug Monitoring;2024-06-03